<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353911</url>
  </required_header>
  <id_info>
    <org_study_id>5172-003</org_study_id>
    <secondary_id>2011-000759-18</secondary_id>
    <nct_id>NCT01353911</nct_id>
  </id_info>
  <brief_title>Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)</brief_title>
  <official_title>A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir
      (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin
      (RBV) in treatment-naïve (TN) participants with chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendment 4 unblinded treatment after an interim analysis for all subsequently enrolled TN
      participants (the Second Cohort) who were receiving grazoprevir 400 or 800 mg daily, and they
      were down-dosed to 100 mg daily between Treatment Week (TW) 3 and TW12 for the remainder of
      the 12-week treatment course.

      Amendment 5 allowed treatment-naïve participants with chronic hepatitis C and compensated
      cirrhosis to be enrolled and receive open-label grazoprevir 100 mg in combination with
      Peg-IFN and RBV, without a corresponding control arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Complete Early Viral Response (cEVR)</measure>
    <time_frame>After 12 weeks of treatment with grazoprevir/boceprevir</time_frame>
    <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). cEVR was defined as undetectable HCV RNA (target not detected [TND]) at Week 12. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs) During the Treatment Period and First 14 Follow-up Days</measure>
    <time_frame>Treatment period plus the first 14 days of follow-up (up to 50 weeks)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Medication Due to AEs During the Treatment Period and First 14 Follow-up Days</measure>
    <time_frame>Treatment period plus the first 14 days of follow-up (up to 50 weeks)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to First Achievement of Undetectable HCV RNA During Treatment</measure>
    <time_frame>From first dose of study medication until first achievement of undetectable HCV RNA (up to 48 weeks of treatment)</time_frame>
    <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. Kaplan Meier summary statistics were calculated for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Rapid Viral Response (RVR)</measure>
    <time_frame>After 4 weeks of treatment with grazoprevir/boceprevir</time_frame>
    <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). RVR was defined as undetectable (TND) HCV RNA at Week 4 of study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of Study Therapy (SVR12)</measure>
    <time_frame>12 weeks after the end of all treatment (up to 60 weeks)</time_frame>
    <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR12 was defined as undetectable (TND) HCV RNA at 12 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After the End of Study Therapy (SVR24)</measure>
    <time_frame>24 weeks after the end of all treatment (up to 72 weeks)</time_frame>
    <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR24 was defined as undetectable (TND) HCV RNA at 24 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Undetectable HCV RNA at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 400 mg/100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 800 mg/100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OL Grazoprevir 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>Orally once daily in AM. Blinded or open-label depending on treatment arm.</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg/100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg/100 mg</arm_group_label>
    <arm_group_label>OL Grazoprevir 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>Four 200 mg capsules orally three times daily.</description>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <other_name>Victrelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Grazoprevir</intervention_name>
    <description>Orally once daily in AM.</description>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Boceprevir</intervention_name>
    <description>Four capsules orally three times daily.</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-interferon alfa-2b</intervention_name>
    <description>1.5 μg/kg/week subcutaneous injection.</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg/100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg/100 mg</arm_group_label>
    <arm_group_label>OL Grazoprevir 100 mg</arm_group_label>
    <other_name>PegIntron</other_name>
    <other_name>Peg-IFN alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>300 mg to 700 mg orally twice daily.</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg/100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg/100 mg</arm_group_label>
    <arm_group_label>OL Grazoprevir 100 mg</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has previously documented chronic hepatitis C genotype 1 (CHC GT 1) infection

          -  Has hepatitis C virus (HCV) ribonucleic acid (RNA value) ≥10,000 IU/mL

          -  Body weight ≥40 kg (88 lbs) and ≤125 kg (275 lbs)

          -  Absence (no medical history or physical findings) of ascites, bleeding esophageal
             varices, hepatic encephalopathy, or other signs and symptoms of decompensated liver
             disease

          -  Had a liver biopsy within 3 years of screening or between screening and Day 1 with
             histology consistent with CHC and no evidence of cirrhosis or hepatocellular carcinoma
             or no other cause for chronic liver disease (for participants with compensated
             cirrhosis, any liver biopsy demonstrating cirrhosis regardless of length of time since
             biopsy)

          -  Female of childbearing potential or a male with female sexual partner who is of
             childbearing potential agrees to use two acceptable methods of birth control from at
             least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of
             study drug, or longer if dictated by local regulations

          -  For participants with compensated cirrhosis, evidence of cirrhosis without evidence of
             hepatocellular carcinoma (confirmed by ultrasound within 4 weeks prior)

        Exclusion Criteria:

          -  Is pregnant, breastfeeding, or plans to become pregnant or donate eggs

          -  Is human immunodeficiency virus (HIV) positive or known to be co-infected with
             hepatitis B virus

          -  Has received prior approved or investigational treatment for hepatitis C

          -  Has evidence of hepatocellular carcinoma or is under evaluation for hepatocellular
             carcinoma

          -  For participants with compensated cirrhosis: alphafetoprotein level of ≥100 ng/mL

          -  Has evidence of active or suspected malignancy, or a history of malignancy, within the
             last 5 years

          -  Has evidence or history of chronic hepatitis not caused by HCV

          -  Is diabetic and/or hypertensive with clinically significant ocular examination
             findings: retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage, or
             any other clinically significant abnormality

          -  Has any known medical condition that could interfere with participation in and
             completion of the study

          -  Pre-existing psychiatric condition including but not limited to moderate or severe
             depression, suicidal or homicidal ideation or attempt, schizophrenia, psychosis,
             bipolar disorder, post traumatic stress disorder, or mania

          -  Is currently participating or has participated in a study with an investigational
             compound or device within 30 days of signing informed consent

          -  Member or family member of study staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug;147(2):366-76.e6. doi: 10.1053/j.gastro.2014.04.006. Epub 2014 Apr 12.</citation>
    <PMID>24727022</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <results_first_submitted>February 3, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2016</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>368 participants enrolled on study. 36 cirrhotic participants received open-label (OL) grazoprevir + peginterferon (Peg-IFN) + ribavirin (RBV), and 332 non-cirrhotic participants were randomized to receive 100, 200, 400, or 800 mg grazoprevir + Peg-IFN + RBV. 43 in the 400 mg group and 36 in the 800 mg group were down-dosed to 100 mg grazoprevir.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OL Grazoprevir 100 mg</title>
          <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P2">
          <title>Grazoprevir 100 mg</title>
          <description>TN non-cirrhotic (NC) participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P3">
          <title>Grazoprevir 200 mg</title>
          <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P4">
          <title>Grazoprevir 400 mg</title>
          <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P5">
          <title>Grazoprevir 800 mg</title>
          <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P6">
          <title>Grazoprevir 400 mg/100 mg</title>
          <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P7">
          <title>Grazoprevir 800 mg/100 mg</title>
          <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="P8">
          <title>Boceprevir 800 mg</title>
          <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="43"/>
                <participants group_id="P7" count="36"/>
                <participants group_id="P8" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="36"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Status Not Recorded</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS); all randomized/enrolled participants who received ≥1 dose of study treatment. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
      <group_list>
        <group group_id="B1">
          <title>OL Grazoprevir 100 mg</title>
          <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B2">
          <title>Grazoprevir 100 mg</title>
          <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B3">
          <title>Grazoprevir 200 mg</title>
          <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B4">
          <title>Grazoprevir 400 mg</title>
          <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B5">
          <title>Grazoprevir 800 mg</title>
          <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B6">
          <title>Grazoprevir 400 mg/100 mg</title>
          <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B7">
          <title>Grazoprevir 800 mg/100 mg</title>
          <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B8">
          <title>Boceprevir 800 mg</title>
          <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="29"/>
            <count group_id="B6" value="43"/>
            <count group_id="B7" value="36"/>
            <count group_id="B8" value="66"/>
            <count group_id="B9" value="368"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="6.9"/>
                    <measurement group_id="B2" value="46.4" spread="11.3"/>
                    <measurement group_id="B3" value="48.3" spread="10.6"/>
                    <measurement group_id="B4" value="44.6" spread="12.5"/>
                    <measurement group_id="B5" value="50.4" spread="13.4"/>
                    <measurement group_id="B6" value="48.3" spread="11.4"/>
                    <measurement group_id="B7" value="50.3" spread="11.2"/>
                    <measurement group_id="B8" value="48.3" spread="11.2"/>
                    <measurement group_id="B9" value="48.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Complete Early Viral Response (cEVR)</title>
        <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). cEVR was defined as undetectable HCV RNA (target not detected [TND]) at Week 12. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
        <time_frame>After 12 weeks of treatment with grazoprevir/boceprevir</time_frame>
        <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Complete Early Viral Response (cEVR)</title>
          <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). cEVR was defined as undetectable HCV RNA (target not detected [TND]) at Week 12. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
          <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="81.3" upper_limit="99.9"/>
                    <measurement group_id="O2" value="80.3" lower_limit="68.7" upper_limit="89.1"/>
                    <measurement group_id="O3" value="85.3" lower_limit="74.6" upper_limit="92.7"/>
                    <measurement group_id="O4" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O5" value="75.9" lower_limit="56.5" upper_limit="89.7"/>
                    <measurement group_id="O6" value="86.0" lower_limit="72.1" upper_limit="94.7"/>
                    <measurement group_id="O7" value="86.1" lower_limit="70.5" upper_limit="95.3"/>
                    <measurement group_id="O8" value="69.7" lower_limit="57.1" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events (AEs) During the Treatment Period and First 14 Follow-up Days</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, was also an AE.</description>
        <time_frame>Treatment period plus the first 14 days of follow-up (up to 50 weeks)</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized/enrolled who received ≥1 dose of study treatment according to treatment actually received. Participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AEs) During the Treatment Period and First 14 Follow-up Days</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, was also an AE.</description>
          <population>All Participants as Treated (APaT) population; all randomized/enrolled who received ≥1 dose of study treatment according to treatment actually received. Participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Medication Due to AEs During the Treatment Period and First 14 Follow-up Days</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, was also an AE.</description>
        <time_frame>Treatment period plus the first 14 days of follow-up (up to 50 weeks)</time_frame>
        <population>APaT population; all randomized/enrolled who received ≥1 dose of study treatment according to treatment actually received. Participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Medication Due to AEs During the Treatment Period and First 14 Follow-up Days</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, was also an AE.</description>
          <population>APaT population; all randomized/enrolled who received ≥1 dose of study treatment according to treatment actually received. Participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to First Achievement of Undetectable HCV RNA During Treatment</title>
        <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. Kaplan Meier summary statistics were calculated for each treatment arm.</description>
        <time_frame>From first dose of study medication until first achievement of undetectable HCV RNA (up to 48 weeks of treatment)</time_frame>
        <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens. Participants in the FAS not achieving TND were censored.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to First Achievement of Undetectable HCV RNA During Treatment</title>
          <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. Kaplan Meier summary statistics were calculated for each treatment arm.</description>
          <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens. Participants in the FAS not achieving TND were censored.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="21.0" upper_limit="29.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="15.0" upper_limit="18.0"/>
                    <measurement group_id="O3" value="28.0" lower_limit="23.0" upper_limit="29.0"/>
                    <measurement group_id="O4" value="16.0" lower_limit="14.0" upper_limit="29.0"/>
                    <measurement group_id="O5" value="16.5" lower_limit="14.0" upper_limit="28.0"/>
                    <measurement group_id="O6" value="27.0" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O7" value="29.0" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O8" value="57.0" lower_limit="57.0" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Rapid Viral Response (RVR)</title>
        <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). RVR was defined as undetectable (TND) HCV RNA at Week 4 of study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
        <time_frame>After 4 weeks of treatment with grazoprevir/boceprevir</time_frame>
        <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Rapid Viral Response (RVR)</title>
          <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). RVR was defined as undetectable (TND) HCV RNA at Week 4 of study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
          <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="54.8" upper_limit="85.8"/>
                    <measurement group_id="O2" value="90.9" lower_limit="81.3" upper_limit="96.6"/>
                    <measurement group_id="O3" value="91.2" lower_limit="81.8" upper_limit="96.7"/>
                    <measurement group_id="O4" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O5" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O6" value="81.4" lower_limit="66.6" upper_limit="91.6"/>
                    <measurement group_id="O7" value="83.3" lower_limit="67.2" upper_limit="93.6"/>
                    <measurement group_id="O8" value="59.1" lower_limit="46.3" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of Study Therapy (SVR12)</title>
        <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR12 was defined as undetectable (TND) HCV RNA at 12 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
        <time_frame>12 weeks after the end of all treatment (up to 60 weeks)</time_frame>
        <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of Study Therapy (SVR12)</title>
          <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR12 was defined as undetectable (TND) HCV RNA at 12 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
          <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="54.8" upper_limit="85.8"/>
                    <measurement group_id="O2" value="89.4" lower_limit="79.4" upper_limit="95.6"/>
                    <measurement group_id="O3" value="91.2" lower_limit="81.8" upper_limit="96.7"/>
                    <measurement group_id="O4" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O5" value="79.3" lower_limit="60.3" upper_limit="92.0"/>
                    <measurement group_id="O6" value="93.0" lower_limit="80.9" upper_limit="98.5"/>
                    <measurement group_id="O7" value="91.7" lower_limit="77.5" upper_limit="98.2"/>
                    <measurement group_id="O8" value="60.6" lower_limit="47.8" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After the End of Study Therapy (SVR24)</title>
        <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR24 was defined as undetectable (TND) HCV RNA at 24 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
        <time_frame>24 weeks after the end of all treatment (up to 72 weeks)</time_frame>
        <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After the End of Study Therapy (SVR24)</title>
          <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR24 was defined as undetectable (TND) HCV RNA at 24 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
          <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="54.8" upper_limit="85.8"/>
                    <measurement group_id="O2" value="86.4" lower_limit="75.7" upper_limit="93.6"/>
                    <measurement group_id="O3" value="92.6" lower_limit="83.7" upper_limit="97.6"/>
                    <measurement group_id="O4" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O5" value="79.3" lower_limit="60.3" upper_limit="92.0"/>
                    <measurement group_id="O6" value="93.0" lower_limit="80.9" upper_limit="98.5"/>
                    <measurement group_id="O7" value="91.7" lower_limit="77.5" upper_limit="98.2"/>
                    <measurement group_id="O8" value="57.6" lower_limit="44.8" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Undetectable HCV RNA at Week 72</title>
        <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
        <time_frame>Week 72</time_frame>
        <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>OL Grazoprevir 100 mg</title>
            <description>Treatment-naïve (TN) cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O2">
            <title>Grazoprevir 100 mg</title>
            <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O3">
            <title>Grazoprevir 200 mg</title>
            <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O4">
            <title>Grazoprevir 400 mg</title>
            <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O5">
            <title>Grazoprevir 800 mg</title>
            <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O6">
            <title>Grazoprevir 400 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O7">
            <title>Grazoprevir 800 mg/100 mg</title>
            <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
          <group group_id="O8">
            <title>Boceprevir 800 mg</title>
            <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Undetectable HCV RNA at Week 72</title>
          <description>Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. 95% confidence intervals provided based on the Clopper-Pearson method.</description>
          <population>FAS; all randomized/enrolled participants who received ≥1 dose of study treatment. A Missing = Failure approach was used for missing data. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="51.9" upper_limit="83.7"/>
                    <measurement group_id="O2" value="80.3" lower_limit="68.7" upper_limit="89.1"/>
                    <measurement group_id="O3" value="86.8" lower_limit="76.4" upper_limit="93.8"/>
                    <measurement group_id="O4" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O5" value="75.9" lower_limit="56.5" upper_limit="89.7"/>
                    <measurement group_id="O6" value="79.1" lower_limit="64.0" upper_limit="90.0"/>
                    <measurement group_id="O7" value="83.3" lower_limit="67.2" upper_limit="93.6"/>
                    <measurement group_id="O8" value="54.5" lower_limit="41.8" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study medication up to 72 weeks</time_frame>
      <desc>APaT population; all randomized/enrolled who received ≥1 dose of study treatment according to treatment actually received. Participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cirr: OL Grazoprevir 100 mg</title>
          <description>TN cirrhotic participants received open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E2">
          <title>Non-cirr: Grazoprevir 100 mg</title>
          <description>TN NC participants received Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E3">
          <title>Non-cirr: Grazoprevir 200 mg</title>
          <description>TN NC participants received Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E4">
          <title>Non-cirr: Grazoprevir 400 mg</title>
          <description>TN NC participants received Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E5">
          <title>Non-cirr: Grazoprevir 800 mg</title>
          <description>TN NC participants received Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E6">
          <title>Non-cirr: Grazoprevir 400 mg/100 mg</title>
          <description>TN NC participants initially were randomized to receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E7">
          <title>Non-cirr: Grazoprevir 800 mg/100 mg</title>
          <description>TN NC participants initially were randomized to receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy. As the result of an interim analysis, these participants were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
        <group group_id="E8">
          <title>Non-cirr: Boceprevir 800 mg</title>
          <description>TN NC participants started a 4 week lead-in with Peg-IFN + RBV, then received Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Segmented hyalinising vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="43"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="64" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E8" events="25" subjects_affected="18" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="9" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="13" subjects_affected="11" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E7" events="13" subjects_affected="12" subjects_at_risk="36"/>
                <counts group_id="E8" events="19" subjects_affected="16" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="66"/>
                <counts group_id="E3" events="28" subjects_affected="25" subjects_at_risk="68"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" events="21" subjects_affected="16" subjects_at_risk="29"/>
                <counts group_id="E6" events="17" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E7" events="29" subjects_affected="19" subjects_at_risk="36"/>
                <counts group_id="E8" events="37" subjects_affected="31" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" events="9" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E8" events="20" subjects_affected="16" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E8" events="13" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="68"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E8" events="16" subjects_affected="15" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="36"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="66"/>
                <counts group_id="E3" events="38" subjects_affected="31" subjects_at_risk="68"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E5" events="19" subjects_affected="16" subjects_at_risk="29"/>
                <counts group_id="E6" events="17" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E7" events="16" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E8" events="30" subjects_affected="27" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="68"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" events="15" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E8" events="24" subjects_affected="23" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" events="13" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="68"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E6" events="18" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E7" events="22" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E8" events="21" subjects_affected="20" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="8" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spleen palpable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E7" events="14" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E8" events="16" subjects_affected="15" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E8" events="15" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="15" subjects_affected="13" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" events="19" subjects_affected="19" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="36"/>
                <counts group_id="E2" events="39" subjects_affected="28" subjects_at_risk="66"/>
                <counts group_id="E3" events="35" subjects_affected="31" subjects_at_risk="68"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E5" events="16" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E7" events="19" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E8" events="44" subjects_affected="35" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E7" events="10" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E8" events="22" subjects_affected="21" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="14" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="66"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="68"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="68"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E8" events="12" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E6" events="12" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E7" events="10" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E8" events="22" subjects_affected="17" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

